Available On Demand
How can companies maximize their potential when launching a gene therapy product?
Gene therapy commercialization is in its infancy. Limited commercial precedent creates significant difficulty in modeling gene therapy revenue and uptake. The single administration nature of the products also presents a unique challenge for companies as the eligible patient population decreases over time.
In this webinar, Trinity Life Sciences’ cell and gene therapy experts evaluate the factors that are unique to forecasting gene therapy markets and share what companies need to know to maximize their revenue potential and successfully navigate the elephant in the room.
Key Webinar Topics
- Key market drivers and product factors contributing to gene therapy opportunity
- Critical launch success factors, including patient identification, site selection and therapy acceptance
- Potential pricing strategies to consider
Executive Director &
Head of Cell & Gene Therapy
Complete the form below to view the on-demand webinar.
Annual State of Global Market Access
In 2023, the life sciences industry saw key therapeutic advances in sickle cell disease, obesity/weight management, and Duchenne muscular dystrophy, among others, and the continued approvals of therapies with cutting edge mechanisms, including the first CRISPR therapy. While 2022 was characterized by accelerated development processes and the rapid evolution of therapeutic standards, 2023 featured increased […]
Cell and Gene Therapies: Six Global Trends We Are Watching in 2024
2023 was a busy year for cell and gene therapies (C>). There were regulatory approvals in the U.S. and EU, including both in rare pediatric conditions with no current effective options (e.g., Duchenne muscular dystrophy (DMD)), as well as in indications where competition is better established (e.g., hemophilia A and B). Towards the end of […]
Empowering Cancer Immunotherapy: Unleashing the Potential of NK Cell Therapies in Oncology
Cell therapies are becoming increasingly incorporated as late-line standards of care across relapsed/refractory oncology indications, with an expanding ability to improve outcomes for a diverse set of tumors and patient subgroups. As the next frontier of personalized and precision medicine continues to grow, Natural Killer (NK) cell therapies offer the potential to penetrate untapped needs […]